Back to Search Start Over

Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA.

Authors :
Lipps C
Northe P
Figueiredo R
Rohde M
Brahmer A
Krämer-Albers EM
Liebetrau C
Wiedenroth CB
Mayer E
Kriechbaum SD
Dörr O
Nef H
Hamm CW
Keller T
Troidl C
Source :
Biomolecules [Biomolecules] 2019 Oct 29; Vol. 9 (11). Date of Electronic Publication: 2019 Oct 29.
Publication Year :
2019

Abstract

Extracellular vesicles are released by numerous cell types of the human body under physiological but also under pathophysiological conditions. They are important for cell-cell communication and carry specific signatures of peptides and RNAs. In this study, we aimed to determine whether extracellular vesicles isolated from patients with pulmonary hypertension show a disease specific signature of small non-coding RNAs and thus have the potential to serve as diagnostic and prognostic biomarkers. Extracellular vesicles were isolated from the serum of 23 patients with chronic thromboembolic pulmonary hypertension (CTEPH) and 23 controls using two individual methods: a column-based method or by precipitation. Extracellular vesicle- associated RNAs were analyzed by next-generation sequencing applying molecular barcoding, and differentially expressed small non-coding RNAs were validated by quantitative real-time polymerase chain reaction (qRT-PCR). We identified 18 microRNAs and 21 P-element induced wimpy testis (PIWI)-interacting RNAs (piRNAs) or piRNA clusters that were differentially expressed in CTEPH patients compared with controls. Bioinformatic analysis predicted a contribution of these piRNAs to the progression of cardiac and vascular remodeling. Expression levels of DQ593039 correlated with clinically meaningful parameters such as mean pulmonary arterial pressure, pulmonary vascular resistance, right ventricular systolic pressure, and levels of N-terminal pro-brain natriuretic peptide. Thus, we identified the extracellular vesicle- derived piRNA, DQ593039, as a potential biomarker for pulmonary hypertension and right heart disease.<br />Competing Interests: C.B.W. has received speaker fees and/or consultant honoraria from Actelion, AOP, Bayer AG, BTG, MSD, and Pfizer. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; and decision to submit the article for publication.

Details

Language :
English
ISSN :
2218-273X
Volume :
9
Issue :
11
Database :
MEDLINE
Journal :
Biomolecules
Publication Type :
Academic Journal
Accession number :
31671920
Full Text :
https://doi.org/10.3390/biom9110666